Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-09-05
2006-09-05
Carlson, Karen Cochrane (Department: 1653)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C435S183000
Reexamination Certificate
active
07101977
ABSTRACT:
The present invention relates to targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor. In a preferred embodiment, the signal transduction pathway factor is an apoptosis-inducing factor, such as granzyme B, granzyme A, or Bax.
REFERENCES:
patent: 4263279 (1981-04-01), Sela et al.
patent: 4414148 (1983-11-01), Jansen et al.
patent: 4522918 (1985-06-01), Schlom et al.
patent: 4590071 (1986-05-01), Scannon et al.
patent: 4650674 (1987-03-01), Aggarwal et al.
patent: 4671958 (1987-06-01), Rodwell et al.
patent: 4677064 (1987-06-01), Mark et al.
patent: 4753894 (1988-06-01), Frankel et al.
patent: 4771128 (1988-09-01), Ferris et al.
patent: 4801578 (1989-01-01), Monsigny et al.
patent: 4831122 (1989-05-01), Buchsbaum et al.
patent: 4863726 (1989-09-01), Stevens et al.
patent: 4870163 (1989-09-01), Rubin et al.
patent: 4888415 (1989-12-01), Lambert et al.
patent: 4894225 (1990-01-01), Zimmerman
patent: 4894227 (1990-01-01), Stevens et al.
patent: 4894443 (1990-01-01), Greenfield et al.
patent: 4935233 (1990-06-01), Bell et al.
patent: 4946778 (1990-08-01), Landner et al.
patent: 4962188 (1990-10-01), Frankel
patent: 4963354 (1990-10-01), Shepard et al.
patent: 4980457 (1990-12-01), Jansen et al.
patent: 5017371 (1991-05-01), Cummins
patent: 5019368 (1991-05-01), Epstein et al.
patent: 5032521 (1991-07-01), White et al.
patent: 5134075 (1992-07-01), Hellstrom et al.
patent: 5359046 (1994-10-01), Capon et al.
patent: 5624827 (1997-04-01), Rosenblum et al.
patent: 5631348 (1997-05-01), Rosenblum et al.
patent: 5720954 (1998-02-01), Hudziak et al.
patent: 5744580 (1998-04-01), Better et al.
patent: 5770195 (1998-06-01), Hudziak et al.
patent: 5837491 (1998-11-01), Better et al.
patent: 5851829 (1998-12-01), Marasco et al.
patent: 6084073 (2000-07-01), Piatak, Jr.
patent: 6099842 (2000-08-01), Pastan et al.
patent: 6140066 (2000-10-01), Lorberboum-Galski et al.
patent: 6214974 (2001-04-01), Rosenblum et al.
patent: 6306626 (2001-10-01), Rosenblum et al.
patent: RE37462 (2001-12-01), Rosenblum et al.
patent: 6531133 (2003-03-01), Lorberboum-Galski et al.
patent: 6599505 (2003-07-01), Rosenblum
patent: 6669938 (2003-12-01), Rosenblum et al.
patent: 6750329 (2004-06-01), Rosenblum et al.
patent: 2002/0090374 (2002-07-01), Yarkoni et al.
patent: 2003/0073163 (2003-04-01), Fernandez et al.
patent: 2003/0134302 (2003-07-01), Fernandez et al.
patent: 2003/0176331 (2003-09-01), Rosenblum et al.
patent: 2003/0186384 (2003-10-01), Barth et al.
patent: 2004/0009477 (2004-01-01), Fernandez et al.
patent: 2004/0013691 (2004-01-01), Rosenblum
patent: B79527/87 (1988-04-01), None
patent: B82047/87 (1988-06-01), None
patent: A13017/88 (1988-09-01), None
patent: A21725/88 (1989-03-01), None
patent: A30753/89 (1989-08-01), None
patent: 0118365 (1984-03-01), None
patent: 0160446 (1985-04-01), None
patent: 0150126 (1985-07-01), None
patent: 0184369 (1985-11-01), None
patent: 0226418 (1986-12-01), None
patent: 0222360 (1987-05-01), None
patent: 0256714 (1988-02-01), None
patent: 0281070 (1988-09-01), None
patent: 0305967 (1989-03-01), None
patent: 0336631 (1989-10-01), None
patent: 0350230 (1990-01-01), None
patent: 0396387 (1990-11-01), None
patent: 1564666 (1978-01-01), None
patent: 2148299 (1985-05-01), None
patent: 86121 (1981-07-01), None
patent: 62209098 (1986-12-01), None
patent: 190200 (1987-08-01), None
patent: WO 85/00974 (1984-08-01), None
patent: WO 86/05098 (1985-07-01), None
patent: WO 86/02945 (1986-05-01), None
patent: WO 87/00056 (1986-06-01), None
patent: WO 88/09343 (1988-12-01), None
patent: WO 88/09344 (1988-12-01), None
patent: WO 89/00999 (1989-02-01), None
patent: WO 89/06692 (1989-07-01), None
patent: WO 90/00405 (1990-01-01), None
patent: WO 91/16071 (1991-10-01), None
patent: WO 94/26910 (1994-11-01), None
patent: IB-97/22364 (1997-06-01), None
patent: IB-97/46259 (1997-12-01), None
patent: IB-98/37901 (1998-09-01), None
patent: WO 99/40198 (1999-08-01), None
patent: IB-99/45128 (1999-09-01), None
patent: IB-99-49059 (1999-09-01), None
patent: WO 99/43840 (1999-09-01), None
patent: WO 99/51620 (1999-10-01), None
patent: WO 99/51766 (1999-10-01), None
patent: WO 00/34317 (2000-06-01), None
patent: WO 03/002598 (2003-01-01), None
U.S. Appl. No. 10/676,725, filed Oct. 1, 2003, Rosenblum.
U.S. Appl. No. 10/926,731, filed Aug. 26, 2004, Rosenblum.
Bendig, “Humanization of rodent monoclonal antibodies by CDR grafting,”METHODS: A Companion to Methods in Enzymology, 8:83-93, 1995.
Berkower, “The promise and pitfalls of monoclonal antibody therapeutics,”Current Opinion in Biotechnology, 7:622-628, 1996.
Bird et al., “Single-chain antigen-binding proteins,”Science, 242:423-426, 1988.
Bjorn et al., “Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins,”Cancer Res., 45:1214-1221, 1985.
Blair et al., “Linkage of cytotoxic agents to immunoglobulins,”J. Immunol. Methods, 59:129-143, 1983.
Blakely et al., “Antibody toxin conjugates: a perspective,”Monoclonal Antibody Therapy. Waldmann (ed). 45:50-90, 1988.
Bolognesi et al., “In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins,”Br. J. Haematol., 110(2):351-361, 2000.
Bradford et al., “A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding,” Analy. Biochem., 72:248-252, 1976.
Bumol et al., “Biosynthetic studies of proteoglycans in human melanoma cells with a monoclonal antibody to a core glycoprotein of chondroitin sulfate proteoglycans,” J. Biol. Chem., 259:12733-12741, 1984.
Chan et al., “Comparison of gallium-67 versus indium-111 monoclonal antibody (96.5, ZME-018) in detection of human melanoma in athymic mice,”J. Nucl. Med., 28:1441-1446, 1987.
Chaudhary et al., “A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin,”Nature, 339:394-397, 1989.
Collen et al., “Recombinant staphylokinase variants with altered immunoreactivity,”Circulation, 94:197-206, 1996.
Cotton et al., “Somatic mutation and the origin of the antibody diversity. Clonal variability of the immunoglobulin produced by MOPC 21 cells in culture,”Eur. J. Immunol., 3:135-140, 1973.
DeLand et al, “A perspective of monoclonal antibodies: past, present, and future,”Seminars in Nuc. Med., 19(3):158-165.
Dermer, “Another anniversary for the war on cancer,”Bio/technology, 12:320, 1994.
Dillman, “Monoclonal antibodies for treating cancer,”Ann. Intern. Med., 111:592-603. 1989.
Dumontet, “[Immunotherapy and cancer: the role of monoclonal antibodies],”J. Chir. (Paris), 126:682-686, 1989.
Engert et al., “Resistance of myeloid leukaemia cell lines to ricin A-chain immunotoxins,”Leuk. Res., 15:1079-1086, 1991.
Falasca et al., “Properties of the ribosome-inactivating proteins gelonin, Momordica charantia inhibitor, and dianthins,”Biochem. J., 207:505-509, 1982.
Fiers et al. “Tumor necrosis factor: a potential anti tumor agent,”J. Interferon Res., 7:627-634, 1987.
Flannery et al., “Immunomodulation: NK cells activated by interferon-conjugated monoclonal antibody against human osteosarcoma”Eur. J. Cancer Clin. Oncol., 20:791-798, 1984.
Frankel et al., “Prospects for immunotoxin therapy in cancer,”Ann. Rev. Med., 37:125-142, 1986.
Freshney, “Culture of animal cells, a manual of basic technique,” Alan R. Liss, Inc, 1983.
Friedman et al., “BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells,”Cancer Res., 53:334-339, 1993.
Frontiera et al., “Sequential use of indium-111 labeled monoclonal antibodies 96.5 and ZME-018 does not increase detection sensitivity for metastatic melanoma,”Clin. Nucl, Med., 14:357-366, 1989.
Ga
Liu Yuying
Rosenblum Michael G.
Carlson Karen Cochrane
Fulbright & Jaworski L.L.P.
Research Development Foundation
LandOfFree
Therapeutic agents comprising pro-apoptotic proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic agents comprising pro-apoptotic proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agents comprising pro-apoptotic proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3607327